Publications by authors named "Bilian Yao"
Background: Recent evidence has indicated that the O-glycosylated PreS2 domain of the middle HBsAg is a distinguishing characteristic that allows the identification of HBsAg of HBV Dane particles and SVPs. This study's objective was to assess the changes in serum O-glycosylated HBsAg levels in CHB patients undergoing ETV or Peg-IFNα treatment.
Methods: Our retrospective study enrolled 86 patients with genotype C CHB.
Article Synopsis
- The study aimed to assess the effectiveness of various tests, including stool and blood markers, in detecting colorectal neoplasia and adenomas.
- The key findings showed that stool methylated syndecan2 (mSDC2) and fecal occult blood test (FOBT) performed better in detecting colorectal neoplasia, with mSDC2 having 100% sensitivity.
- However, none of the tests, including CEA, CA125, and CA199, were effective for adenoma detection, and the combination of mSEPT9 and mSDC2 yielded the best results for colorectal neoplasia.
Article Synopsis
- - The study examines how genetic variations linked to Gilbert syndrome (GS), which causes mild bilirubin elevation, impact the outcomes of hepatitis B virus (HBV) infections in patients.
- - Among the 175 patients studied, those with variant GS had a significantly lower incidence of cirrhosis or hepatocellular carcinoma compared to those with the wild-type gene (13.14% vs. 78.95%).
- - Results suggest that rarer genetic variants correlate with a better prognosis for HBV infection, indicating the potential therapeutic role of bilirubin elevation in managing the infection.
Background And Aims: Monocyte/macrophage-associated CD163 is an indicator of the severity of liver inflammation and cirrhosis, but the difference of soluble CD163 (sCD163) levels in chronic hepatitis B (CHB) patients and hepatitis B surface antigen (HBsAg)-loss patients is unclear. Herein, we aimed to compare the sCD163 levels in CHB patients and HBsAg-loss patients with or without antiviral treatment.
Methods: sCD163 and CD163 expression on monocytes were compared among four groups, healthy subjects, treatment-naïve CHB patients, spontaneous HBsAg-loss patients, and treatment-related HBsAg-loss patients.
Article Synopsis
- Genome-wide studies reveal that the rs12979860 polymorphism in the IL28B gene is linked to treatment responses for chronic hepatitis C.
- In a study of 259 Chinese Han patients with HCV, the majority had the CC genotype, which was significantly associated with better rates of end-of-treatment response (ETR) and sustained virological response (SVR).
- This identification of rs12979860 as a predictive marker for treatment outcomes highlights its potential to explain higher SVR rates in this specific population compared to global averages.
Article Synopsis
- The hepatitis C virus F protein can provoke specific CD4(+) T cell responses in patients, indicating its role in immunity.
- Researchers used HLA-transgenic mouse models and human blood samples to identify specific peptide epitopes of the F protein that activate T cells.
- This study highlights the importance of the F protein in understanding the immune response and potential complications during chronic hepatitis C infection.
Article Synopsis
- The study investigates the immune response to the hepatitis C virus (HCV) F protein in patients, finding that 68% of those tested had antibodies against it.
- It reveals that changes in anti-F antibodies during interferon therapy were significantly different between patients who responded to the treatment and those who did not.
- The research suggests a potential link between anti-F antibody levels and achieving a sustained virological response (SVR), indicating that the F protein could play a role in HCV treatment outcomes.